How Myelodysplastic-Myeloproliferative Diseases Medications Work

Myelodysplastic-myeloproliferative diseases (MDS/MPN) are a group of rare blood disorders characterized by ineffective hematopoiesis, leading to anemia, thrombocytopenia, and neutropenia. The primary goal of treatment is to improve quality of life and reduce the risk of transformation to acute leukemia.

Gold Standard Therapies

The gold standard for treating MDS/MPN involves the use of hypomethylating agents (HMA), which include:

• Azacitidine: works by inhibiting DNA methyltransferase, leading to increased expression of tumor suppressor genes and decreased proliferation of malignant cells.
• Decitabine: also a DNA methyltransferase inhibitor, promoting epigenetic reprogramming and apoptosis in malignant cells.

Alternative Therapies

For patients who do not respond to HMAs or have contraindications, alternative therapies may be considered:

• Lenalidomide: an immunomodulatory agent that promotes apoptosis and inhibits proliferation of malignant cells.
• Pegylated interferon-alpha: a cytokine therapy that modulates immune response and inhibits tumor growth.
• Immunosuppressive therapy (e.g., Cyclosporine): may be used to manage symptoms and prevent complications, such as thrombocytopenia or anemia.